ClinicalTrials.gg

Azurity Pharmaceuticals clinical trials

Also known as CutisPharma.

Part of QHP Capital.

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 78 studies whose lead sponsor is Azurity Pharmaceuticals or one of 4 companies grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 15, 2026.

Our grouping of 5 registry names, not the registry’s. See them and correct one ↓

Pipeline: 1 program

Each counted once: 1 with a study Azurity Pharmaceuticals leads registered in the last two years.

  • Phase 4 (approved, new studies)

The 1 program — sign in to see the list, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Azurity Pharmaceuticals’ own registered studies; Azurity Pharmaceuticals’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Azurity Pharmaceuticals’ studies test, most open studies first — 19 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 9 more

Coming up

2 of Azurity Pharmaceuticals’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. M
  6. A
  7. M
  8. 1J
  9. J
  10. A
  11. 1S
  12. O
  13. N

Add all 2 to your calendar (.ics) → With an account.

All 78 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now45%Recruiting 2 · Not yet recruiting 2
  • Completed6178%
  • Stopped early1114%Terminated 9 · Withdrawn 2
  • Status unknown or other23%

Phase

  • Phase 326
  • Phase 224
  • Phase 118
  • Phase 49

Where

  • United States70
  • Canada10
  • Poland9
  • Hungary8
  • Ukraine4
  • Germany4

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 1014
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 226

By the year each study started; 9 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Azurity Pharmaceuticals.

  • XenoPort, Inc.
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    26 studies →
  • AMAG Pharmaceuticals, Inc.
    Acquired — became part of Azurity Pharmaceuticals, Mar 14, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    24 studies →
  • Arbor Pharmaceuticals, Inc.
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    15 studies →
  • Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
    Acquired — became part of Azurity Pharmaceuticals, Mar 14, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    11 studies →
  • Azurity Pharmaceuticals
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies

Focus areas

Conditions Azurity Pharmaceuticals leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 78. Browse all 78 →